Nepveu, Olivier
Orione, Charles
Tromeur, Cécile
Fauché, Alexandre
L’heveder, Cecile
Guegan, Marie
Lemarié, Catherine
Jimenez, David
Leroyer, Christophe
Lacut, Karine
Couturaud, Francis
Le Mao, Raphael http://orcid.org/0000-0003-4489-5697
Funding for this research was provided by:
Agence Nationale de la Recherche
Article History
Received: 4 October 2021
Accepted: 8 December 2021
First Online: 4 January 2022
Declarations
:
: This study was conducted following the amended Declaration of Helsinki. The Ethics Committee of Brest University Hospital approved the study protocol (IRB approval number: CCP Ouest 6–390). Written informed consent was obtained from all participants before inclusion.
: not applicable.
: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Nepveu declares he has no competing interests related to this research. Dr. Orione declares he has no competing interests related to this research. Dr. Tromeur declares she has no competing interests related to this research. Dr. L’heveder declares she has no competing interests related to this research. Ms. Guegan declares she has no competing interests related to this research. Dr. Lemarié declares she has competing interests related to this research. Dr. Fauché declares he has competing interests related to this research. Dr. Jimenez declares he has no competing interests related to this research. Dr. Leroyer reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer and Astra Zeneca and having received travel support from Bayer, Daiichi Sankyo, Leo Pharma, Intermune and Actelion. Dr. Lacut reports having received personal fees from Bayer-Health Care, Bristol-Myers Squibb and Boehringer Ingelheim. Dr. Couturaud reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer and Astra Zeneca and having received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Leo Pharma, Intermune and Actelion. Dr. Le Mao declares he has no conflict of interest related to this research.